ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

A new year of investing insights.

Pleas note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...

When it comes to individual shares, avoiding big losers is every bit as important as finding winners. This quick test could make that easier.

This article collates the work of our colleagues in the US and Europe on Monday's AI stock sell-off with added reaction from ...

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, ...

Getting regular, growing income from stocks is tougher with the dividend yield on the ASX nearing 25-year lows. Here are some ...

Listed property has several perks but investors seeking diversification and better value might want to look beyond the index.

Morningstar Investment Management's Chief Investment Officer for Asia Pacific weighs in on the weak Aussie dollar and what ...

Can Nvidia maintain its dominance in chipmaking if its cutting-edge technology isn’t as crucial as some first thought?

However, the outlook for data centres electricity demand trends towards the bull-case scenario from the last demand forecast.

The Federal Government faces an uphill battle to make retired Australians spend more. Let's hope they don't go overboard.